Aptose Biosciences Files 8-K
Ticker: APTOF · Form: 8-K · Filed: Dec 9, 2024 · CIK: 882361
Sentiment: neutral
Topics: 8-K, financial-reporting, disclosure
Related Tickers: APTO
TL;DR
APTO filed an 8-K on Dec 9, 2024, covering Reg FD and financials. Formerly Lorus/Imutec.
AI Summary
Aptose Biosciences Inc. filed an 8-K on December 9, 2024, reporting on Regulation FD disclosures and financial statements. The company, formerly known as Lorus Therapeutics Inc. and Imutec Pharma Inc., is incorporated in Canada and operates in the biological products sector.
Why It Matters
This filing provides important updates on Aptose Biosciences' regulatory compliance and financial reporting, which are crucial for investors to assess the company's current status.
Risk Assessment
Risk Level: low — This is a routine filing of an 8-K for financial statements and disclosures, not indicating any immediate operational or financial distress.
Key Players & Entities
- Aptose Biosciences Inc. (company) — Registrant
- Lorus Therapeutics Inc. (company) — Former company name
- Imutec Pharma Inc (company) — Former company name
- December 9, 2024 (date) — Date of earliest event reported
FAQ
What is the primary purpose of this 8-K filing?
This 8-K filing serves to report on Regulation FD disclosures and to provide financial statements and exhibits.
When was the earliest event reported in this filing?
The earliest event reported in this filing occurred on December 9, 2024.
What is Aptose Biosciences Inc.'s Standard Industrial Classification code?
Aptose Biosciences Inc. is classified under SIC code 2836, which pertains to Biological Products (No Diagnostic Substances).
What were Aptose Biosciences Inc.'s former company names?
Aptose Biosciences Inc. was formerly known as Lorus Therapeutics Inc. and prior to that, Imutec Pharma Inc.
In which jurisdiction is Aptose Biosciences Inc. incorporated?
Aptose Biosciences Inc. is incorporated in Canada.
Filing Stats: 506 words · 2 min read · ~2 pages · Grade level 9.7 · Accepted 2024-12-09 12:05:43
Filing Documents
- f8k_120924.htm (8-K) — 15KB
- exh_991.htm (EX-99.1) — 10KB
- 0001171843-24-006814.txt ( ) — 226KB
- gnw-20190101.xsd (EX-101.SCH) — 3KB
- gnw-20190101_def.xml (EX-101.DEF) — 25KB
- gnw-20190101_lab.xml (EX-101.LAB) — 33KB
- gnw-20190101_pre.xml (EX-101.PRE) — 22KB
- f8k_120924_htm.xml (XML) — 3KB
01. Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure. On December 9, 2024, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference. In accordance with General Instruction B.2 of Form 8-K, the information in the press release attached as Exhibit 99.1 hereto shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Press Release dated December 9, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Aptose Biosciences Inc. Date: December 9, 2024 By: /s/ William G. Rice, Ph.D. William G. Rice, Ph.D. President and Chief Executive Officer